FI852626L - Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA - Google Patents

Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA

Info

Publication number
FI852626L
FI852626L FI852626A FI852626A FI852626L FI 852626 L FI852626 L FI 852626L FI 852626 A FI852626 A FI 852626A FI 852626 A FI852626 A FI 852626A FI 852626 L FI852626 L FI 852626L
Authority
FI
Finland
Prior art keywords
necrosis factor
tumor necrosis
dna encoding
human tumor
producing human
Prior art date
Application number
FI852626A
Other languages
English (en)
Swedish (sv)
Other versions
FI95472B (fi
FI852626A0 (fi
FI95472C (fi
Inventor
Bharat Bhushan Aggarwal
David Vannorman Goeddel
Sang He Lee
Glenn Evan Nedwin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/677,257 external-priority patent/US4650674A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI852626A0 publication Critical patent/FI852626A0/fi
Publication of FI852626L publication Critical patent/FI852626L/fi
Publication of FI95472B publication Critical patent/FI95472B/fi
Application granted granted Critical
Publication of FI95472C publication Critical patent/FI95472C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
FI852626A 1984-07-05 1985-07-03 Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA FI95472C (fi)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US62806084A 1984-07-05 1984-07-05
US62795984A 1984-07-05 1984-07-05
US62805984A 1984-07-05 1984-07-05
US62795984 1984-07-05
US62806084 1984-07-05
US62805984 1984-07-05
US67715684A 1984-12-03 1984-12-03
US67745484A 1984-12-03 1984-12-03
US06/677,257 US4650674A (en) 1984-07-05 1984-12-03 Synergistic cytotoxic composition
US67745484 1984-12-03
US67715684 1984-12-03
US67725784 1984-12-03

Publications (4)

Publication Number Publication Date
FI852626A0 FI852626A0 (fi) 1985-07-03
FI852626L true FI852626L (fi) 1986-01-06
FI95472B FI95472B (fi) 1995-10-31
FI95472C FI95472C (fi) 1996-02-12

Family

ID=27560190

Family Applications (2)

Application Number Title Priority Date Filing Date
FI852626A FI95472C (fi) 1984-07-05 1985-07-03 Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
FI943750A FI98217C (fi) 1984-07-05 1994-08-15 Menetelmä nekroositekijän valmistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI943750A FI98217C (fi) 1984-07-05 1994-08-15 Menetelmä nekroositekijän valmistamiseksi

Country Status (20)

Country Link
EP (1) EP0168214B1 (fi)
JP (4) JP2557341B2 (fi)
AT (1) ATE113295T1 (fi)
AU (1) AU599571B2 (fi)
BG (1) BG60250B2 (fi)
CZ (1) CZ283149B6 (fi)
DE (2) DE19975064I2 (fi)
DK (2) DK169894B1 (fi)
FI (2) FI95472C (fi)
GR (1) GR851626B (fi)
HU (1) HU209153B (fi)
IE (1) IE65426B1 (fi)
IL (2) IL75717A (fi)
LU (1) LU90456I2 (fi)
NL (1) NL990033I2 (fi)
NO (1) NO852673L (fi)
NZ (1) NZ212632A (fi)
PL (1) PL155778B1 (fi)
SK (1) SK279897B6 (fi)
YU (1) YU47968B (fi)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
EP0368367A1 (en) * 1984-12-21 1990-05-16 Biogen, Inc. Purification, production and use of tumor necrosis factors
JPS61155330A (ja) * 1984-12-28 1986-07-15 Denichi Mizuno 蛋白質標品
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
CA1340998C (en) * 1986-02-04 2000-05-23 Den'ichi Mizuno Dnas and processes for their preparation, novel plasmids possessing them, novel polypeptides and processes for their preparation and novel anti-tumor agents comprising said polypeptides
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
ATE107362T1 (de) * 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
JPH0817712B2 (ja) * 1986-06-20 1996-02-28 大日本製薬株式会社 新規ヒトｔｎｆポリペプチド変異体
US4857314A (en) * 1986-07-18 1989-08-15 Health Research , Inc. C-reactive proteins in treatment of animal and human cancers
CA1340698C (en) * 1986-07-25 1999-08-10 Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo Preparation and uses of interferon-gamma
PT84869B (pt) * 1986-07-31 1990-11-07 Genentech Inc Metodo para a profilaxia e tratamento de infeccoes por retrovirus e processo para a preparacao de composicoes para esse fim, contendo factor de necrose tumoral
US5002876A (en) * 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
DE69029970T2 (de) 1989-08-16 1997-06-19 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
CA2078000C (en) * 1990-03-12 2001-10-02 Deborah A. Rathjen Neutrophil stimulating peptides
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
EP0682705A1 (en) * 1993-02-03 1995-11-22 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
JPH10504441A (ja) 1994-03-07 1998-05-06 カイロン コーポレイション Ｔｎｆ形成阻害のための組成物およびその使用
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
IL120979A0 (en) * 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
PT2953634T (pt) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Métodos de expansão ou depleção das células t reguladoras

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH65623A (de) * 1913-08-02 1914-07-01 Siemens Ag Zeitrelais mit Wechselstrommotor und dessen Drehmoment entgegenwirkender Feder
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS60226816A (ja) * 1984-11-16 1985-11-12 Asahi Chem Ind Co Ltd 抗腫瘍活性をもつヒト由来蛋白質
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
JPS60166696A (ja) * 1984-02-08 1985-08-29 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄνａ
JPS60221092A (ja) * 1984-04-18 1985-11-05 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄｎａ
EP0148311B1 (en) * 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha A novel physiologically active polypeptide
JPS60137292A (ja) * 1983-12-26 1985-07-20 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドの遺伝情報を有するポリデオキシリボ核酸、該ポリデオキシリボ核酸を含む複製可能な組換ｄνａ、該複製可能な組換ｄνａで形質転換された微生物または細胞、新規生理活性ポリペプチド及びその製造方法
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
JPS60232097A (ja) * 1984-04-23 1985-11-18 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子ポリペプチドの製造法
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
JP2515975B2 (ja) * 1985-02-26 1996-07-10 大日本製薬株式会社 抗腫瘍作用を有するポリペプチド

Also Published As

Publication number Publication date
DK305885D0 (da) 1985-07-04
IE851691L (en) 1986-01-05
YU113285A (en) 1991-04-30
DE19975064I1 (de) 2005-09-29
DE3587939D1 (de) 1994-12-01
EP0168214A3 (en) 1987-12-16
DK75694A (da) 1994-06-24
JPH083061A (ja) 1996-01-09
ATE113295T1 (de) 1994-11-15
CZ283149B6 (cs) 1998-01-14
AU4465285A (en) 1986-01-09
PL254399A1 (en) 1986-06-17
EP0168214A2 (en) 1986-01-15
SK506785A3 (en) 1999-05-07
PL155778B1 (pl) 1992-01-31
DE3587939T2 (de) 1995-04-27
IL75717A0 (en) 1985-11-29
IL105271A (en) 1995-07-31
NL990033I1 (nl) 1999-12-01
NO852673L (no) 1986-01-06
YU47968B (sh) 1996-08-13
DK171418B1 (da) 1996-10-21
FI98217C (fi) 1997-05-12
EP0168214B1 (en) 1994-10-26
HU209153B (en) 1994-03-28
FI95472B (fi) 1995-10-31
JPH07291997A (ja) 1995-11-07
LU90456I2 (fr) 1999-12-06
FI98217B (fi) 1997-01-31
JPS6140221A (ja) 1986-02-26
AU599571B2 (en) 1990-07-26
IL75717A (en) 1994-11-28
HUT38125A (en) 1986-04-28
GR851626B (fi) 1985-11-26
FI852626A0 (fi) 1985-07-03
DK169894B1 (da) 1995-03-27
NL990033I2 (nl) 2000-11-01
IE65426B1 (en) 1995-11-01
JP2614989B2 (ja) 1997-05-28
FI943750A (fi) 1994-08-15
CZ506785A3 (en) 1997-07-16
FI95472C (fi) 1996-02-12
BG60250B1 (bg) 1994-03-24
DE19975064I2 (de) 2005-11-03
FI943750A0 (fi) 1994-08-15
JPH0928387A (ja) 1997-02-04
BG60250B2 (bg) 1994-03-24
JP2557341B2 (ja) 1996-11-27
NZ212632A (en) 1991-05-28
SK279897B6 (sk) 1999-05-07
DK305885A (da) 1986-03-14

Similar Documents

Publication Publication Date Title
FI95472B (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
PT1380587E (pt) Oxazolo, thiazolo e selenazolo -(4, 5-c )- naftiridina- 4- amina e analogos destes compostos
ATE414152T1 (de) Muteine von ifn-beta
NZ227944A (en) Synergistic pharmaceutical composition of a hybrid interferon and a muramylpeptide
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
EP0248583A3 (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
ES8800984A1 (es) Un metodo para obtener adn que codifica factor de necrosis de tumores mutante
RU95101019A (ru) Способ получения фактора некроза опухоли, фактор некроза опухоли, днк, клетка, композиция

Legal Events

Date Code Title Description
BB Publication of examined application
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L161

Extension date: 20100702

FG Patent granted

Owner name: GENENTECH, INC.

MA Patent expired